Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2002-07-23
2010-11-30
Shibuya, Mark L (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007930, C435S007940, C435S007950, C436S518000, C436S016000, C436S071000, C436S811000, C530S389300, C530S391300
Reexamination Certificate
active
07842463
ABSTRACT:
There is disclosed a method of diagnosing early stage renal impairment in humans, characterized by the following steps:measuring the amount of apoA-IV in a body liquid or tissue sample of a human, andcomparing the measured amount of apoA-IV with a reference value.
REFERENCES:
Lagrost et al., 1989. Evidence for high density lipoproteins as the major apolipoprotein A-IV-containing fraction in normal human serum. Journal of Lipid Research 30: 1525-1534.
Fu et al., 1996. Translational regulation of human p53 gene expression. EMBO Journal 15: 4392-4401.
Guo et al., 2002. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by . . . inducers that activate gene expression through ligand-activated transcription factor pathways. J. Pharmacol. Exp. Therapeutics 300: 206-212.
Vallejo et al., 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. Biochimie 82: 1129-1133.
Yokota et al., 1988. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475.
Aalto-Setälä et al., “Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior,”J. Clin. Invest., 93:1776-1786, 1994.
Apfelbaum et al., “Apolipoprotein A-IV synthesis in rat intestine: regulation by dietary triglyceride,”Am. J. Physiol., 252:G662-G666, 1987.
Attman and Alaupovic, “Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis,”Nephron, 57:401-410, 1991.
Attman et al., “Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure,”Nephrol. Dial. Transplant, 11:63-69, 1996.
Attman et al., “Serum apolipoprotein profile of patients with chronic renal failure,”Kidney Int., 32:368-375, 1987.
Bostom and Lathrop, “Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes,”Kidney Int., 52:10-20, 1997.
Chen and Albers, “Activation of lecithin cholesterol acyltransferase by apolipoproteins E-2, E-3 and A-IV isolated form human plasma,”Biochim. Biophys. Acta, 836:279-285, 1985.
Cockcroft and Gault, “Prediction of creatinine clearance from serum creatinine,”Nepron, 16:31-41, 1976.
Cohen et al., “Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apoliopoprotien A-IV,”J. Clin. Invest., 99:1906-1916, 1997.
Diallinga-Thie et al., “Tissue sites of degradation of high density lipoprotein apolipoprotein A-IV in rats,”Arteriosclerosis, 6:277-284, 1986.
Diepliner et al., “Plasma cholesterol metabolism in end-stage renal disease: difference between treatment by hemodialysis or peritoneal dialysis,”J. Clin. Invest., 77:1071-1083, 1986.
Dieplinger et al, “Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease,”Eur. J. Clin. Invest., 22(3):166-174, 1992.
Duverger et al., “Characterisation of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid,”Arterioscler. Thromb., 13:126-132, 1993.
Duverger et al., “Protection against atherogenesis in mice mediated by human apolipoprotein A-IV,”Science, 273:966-968, 1996.
Dvorin et al., “A determinant for binding and uptake of high density lipoproteins by rat hepatocytes,”J. Biol. Chem., 261(33):15714-15718, 1986.
Fujimoto et al., “Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation,”Am. J. Physiol., 262:G1002-G1006, 1992.
Gaspari et al., “Precision of plasma clearacne of iohexol for estimation of GFR in patients with renal disease,”J. Am. Soc. Nephrol., 9:310-313, 1998.
Goldberg et al., “Lipoprotein ApoC-II actiation of lipoprotein lipase. Modulation by apolipoprotein A-IV,”J. Biol. Chem., 265:4266-4272, 1990.
Green et al., “Human apolipoprotein A-IV. Intestinal origin and distribution in plasma,”J. Clin. Invest., 65:11-919, 1980.
Guyard-Dangremon et al., “Comparative effects of purified apolipoproteins A-I, A-II and A-IV on cholseteryl ester transfer protein activity,”J. Lipid Res., 35:982-992, 1994.
Kronenberg et al., “Effect of sample storage on the mesurement of lipoprotein(a), apolipoproteins B and A-IV, total and high-density lipoprotein cholesterol and triglycerides,”J. Lipid Res., 35:1318-1328, 1994.
Kronenberg et al., “Lipoprotein(a) serum concentrations and polipoprotein(a) phenotypes in mild and moderate renal failure,”J. Am. Soc. Nephrol., 11:105-115, 2000.
Kronenberg et al., “Low apolipoprotein A-IV plasma concentrations in men with coranary artery disease,”J. Am. Coll. Cardiol., 36:751-757, 2000.
Kronenberg et al., “Multicentre study of lipoprotein(a) and apolipoprotein(a) phenotypes in patints with end-stage renal disease treated by hemodialysis or continuous amulatory peritoneal dialysis,”J. Am. Soc. Nephrol., 6:110-120, 1995.
Kronenberg, “Homocysteine, lipoprotien(a) and fibrinogen: metabolic risk factors for cardiobascular complications of chronic renal disease,”Curr. Opin. Nephrol. Hypertens, 7:271-278, 1998.
London and Drüeke, “Atherosclerosis and arteriosclerosis in chroninc renal failure,”Kidney Int., 51:1678-1695, 1997.
Massey et al., “High serum apolipoprotein AIV levels in renal transplant recipients,”Clin. Nephrol., 55(2):156-158, 2001.
Nestel et al., “Increased lipoprotein-remnant formation in chronic renal failure,”New England Journal of Medicine, 307(6):329-333, 1982.
Rosseneu et al., “Human apolipoprotein A-IV quantitation by sandwich enzyme linked immunosorbent assay,”Clin. Chem., 34:739-743, 1988.
Seishima et al., “An increased apo A-IV serum concentration of patints with chronic renl failure on hemodialysis,”Clin. Chim. Acta, 167:303-311, 1987.
Seishima et al., “Increased serum apoA-IV concentrations in experimental uremic rats,”J. Lipid Res., 33:1441-1447, 1992.
Stein et al., “The role of apoliopoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine,”Biochim. Biophys. Acta, 878:7-13, 1986.
Steinmetz and Utermann, “Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV,”J. Biol. Chem., 260:2258-2264, 1985.
Steinmetz et al., “Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites promotes cholesterol efflux from adipose cells,”J. Biol. Chem., 265:7859-7863, 1990.
Sun et al., “Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations,”Atherosclerosis, 151:381-388, 2000.
Utermann et al., “Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quandification,”Eur. J. Biochem., 99:333-343, 1979.
Verges et al., “Apolipoprotein A-IV levels and phenotype distribution in NIDDM,”Diabetes Care, 17:810-817, 1994.
Verges et al., “Macrovascular disease is associated with increased plasma apolipoprotien A-IV levels in NIDDM,”Diabetes, 46:125-132, 1997.
Von Eckardstein et al., “Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma,”Arterioscler. Thromb. Vasc. Biol., 15:1755-1763, 1995.
Wienstock et al., “Decreased HDL cholesterol levels but normal lipid avsorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice,”J. Lipid Res., 38:1782-1794, 1997.
Miyata et al., “Serum apolipoprotein A-IV levels increase in diabetic patients with nephropathy,”The Journal of Japan Atherosclerosis Society,15
Fulbright & Jaworski LLP
Grun James L
Shibuya Mark L
Vitateq Biotechnology Gmbh
LandOfFree
Method of diagnosing early stage renal impairment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of diagnosing early stage renal impairment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosing early stage renal impairment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197524